New patient trials surrounding the medication Retatrutide , specifically the 120mg formulation referred to as ZPHC, suggest a considerable impact on physique decrease and associated chronic conditions . Researchers believe that this dual compound, targeting both GLP-1 and GIP pathways , has the potential to provide a noteworthy advance in the trea